Compare · ABBV vs NATR
ABBV vs NATR
Side-by-side comparison of AbbVie Inc. (ABBV) and Nature's Sunshine Products Inc. (NATR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and NATR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $481.40B, about 2176.5x NATR ($221.2M).
- Over the past year, ABBV is up 20.0% and NATR is down 14.0% - ABBV leads by 34.0 points.
- ABBV has hit the wire 16 times in the past 4 weeks while NATR has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 5 for NATR).
- Company
- AbbVie Inc.
- Nature's Sunshine Products Inc.
- Price
- $276.40+1.45%
- $12.64+0.64%
- Market cap
- $481.40B
- $221.2M
- 1M return
- +8.38%
- -6.99%
- 1Y return
- +20.01%
- -14.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 5
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Nature's Sunshine Products Inc.
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. The company offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. It also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. The company offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is based in Lehi, Utah.
Latest ABBV
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- SEC Form 8-K filed by AbbVie Inc.
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
- AbbVie to Host Third-Quarter 2026 Earnings Conference Call
- FDA Approval for JUVMO issued to ABBVIE INC
- AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
- AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
- AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Latest NATR
- EVP, Chief Financial Officer Perkins Ruth Ann was granted 75,433 shares (SEC Form 4)
- SEC Form 3 filed by new insider Perkins Ruth Ann
- SVP, Chief Accounting Officer Lanoy Jonathan David was granted 7,210 shares, increasing direct ownership by 15% to 55,602 units (SEC Form 4)
- Large owner Prescott Group Capital Management, L.L.C. bought $293,800 worth of shares (20,000 units at $14.69) (SEC Form 4)
- Large owner Prescott Group Capital Management, L.L.C. bought $2,318,912 worth of shares (141,389 units at $16.40) (SEC Form 4)
- SEC Form 10-Q filed by Nature's Sunshine Products Inc.
- Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Nature's Sunshine Reports Second Quarter 2026 Results
- Nature's Sunshine Appoints Ruth Perkins as Executive Vice President and Chief Financial Officer
- Nature’s Sunshine Appoints Janine Weber as Executive Vice President and President, North America